Functional variants in notch pathway genes NCOR2, NCSTN, and MAML2 predict survival of patients with cutaneous melanoma

Cancer Epidemiology Biomarkers and Prevention

Volumn 24, Issue 7, 2015, Pages 1101-1110

  Zhang, Weikang ^a,b   Liu, Hongliang ^a   Liu, Zhensheng ^a   Zhu, Dakai ^c   Amos, Christopher I ^c   Fang, Shenying ^d   Lee, Jeffrey E ^d   Wei, Qingyi ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NOTCH RECEPTOR; DNA; DNA BINDING PROTEIN; MAML2 PROTEIN, HUMAN; MEMBRANE PROTEIN; NCOR2 PROTEIN, HUMAN; NICASTRIN PROTEIN; NUCLEAR PROTEIN; SECRETASE; SILENCING MEDIATOR OF RETINOID AND THYROID HORMONE RECEPTOR; TRANSCRIPTION FACTOR;

ADULT; ARTICLE; CANCER PATIENT; CANCER STAGING; CLINICAL FEATURE; CUTANEOUS MELANOMA; DISEASE SPECIFIC SURVIVAL; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HIGH RISK POPULATION; HUMAN; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MAML2 GENE; MITOSIS RATE; NCOR2 GENE; NCSTN GENE; OVERALL SURVIVAL; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL PREDICTION; SURVIVAL RATE; ADOLESCENT; AGED; EPIDEMIOLOGY; GENETIC POLYMORPHISM; GENETIC VARIATION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; MELANOMA; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; TEXAS; TRENDS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMYLOID PRECURSOR PROTEIN SECRETASES; DNA, NEOPLASM; DNA-BINDING PROTEINS; FEMALE; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; MALE; MELANOMA; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NUCLEAR PROTEINS; NUCLEAR RECEPTOR CO-REPRESSOR 2; POLYMORPHISM, GENETIC; PROGNOSIS; SURVIVAL RATE; TEXAS; TRANSCRIPTION FACTORS; YOUNG ADULT;

EID: 84941772031     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-1380-T     Document Type: Article

References (40)

1. Webb T. SNPs: can genetic variants control cancer susceptibility? J Natl Cancer Inst 2002;94:476-8.
2. Erichsen HC, Chanock SJ. SNPs in cancer research and treatment. Br J Cancer 2004;90:747-51.
3. Bishop DT, Demenais F, Iles MM, Harland M, Taylor JC, Corda E, et al. Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet 2009;41:920-5.
4. Amos CI, Wang LE, Lee JE, Gershenwald JE, Chen WV, Fang S, et al. Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. Hum Mol Genet 2011;20:5012-23.
5. Brown KM, Macgregor S, Montgomery GW, Craig DW, Zhao ZZ, Iyadurai K, et al. Common sequence variants on 20q11.22 confer melanoma susceptibility. Nat Genet 2008;40:838-40.
6. Teerlink C, Farnham J, Allen-Brady K, Camp NJ, Thomas A, Leachman S, et al. A unique genome-wide association analysis in extended Utah highrisk pedigrees identifies a novel melanoma risk variant on chromosome arm 10q. Hum Genet 2012;131:77-85.
7. Nan H, Xu M, Zhang J, Zhang M, Kraft P, Qureshi AA, et al. Genomewide association study identifies nidogen 1 (NID1) as a susceptibility locus to cutaneous nevi and melanoma risk. Hum Mol Genet 2011; 20:2673-9.
8. Rendleman J, Shang S, Dominianni C, Shields JF, Scanlon P, Adaniel C, et al. Melanoma risk loci as determinants of melanoma recurrence and survival. J Transl Med 2013;11:279.
9. Yin J, Liu H, Liu Z, Wang LE, Chen WV, Zhu D, et al. Genetic variants in fanconi anemia pathway genes BRCA2 and FANCA predict melanoma survival. J Invest Dermatol 2015;135:542-50.
10. Li C, Yin M, Wang LE, Amos CI, Zhu D, Lee JE, et al. Polymorphisms of nucleotide excision repair genes predict melanoma survival. J Invest Dermatol 2013;133:1813-21.
11. Meyle KD, Guldberg P. Genetic risk factors for melanoma. Hum Genet 2009;126:499-510.
12. Moriyama M, Osawa M, Mak SS, Ohtsuka T, Yamamoto N, Han H, et al. Notch signaling via Hes1 transcription factor maintains survival of melanoblasts and melanocyte stem cells. J Cell Biol 2006; 173:333-9.
13. Panelos J, Massi D. Emerging role of Notch signaling in epidermal differentiation and skin cancer. Cancer Biol Ther 2009;8:1986-93.
14. Hoek K, Rimm DL, Williams KR, Zhao H, Ariyan S, Lin A, et al. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res 2004;64:5270-82.
15. Balint K, Xiao M, Pinnix CC, Soma A, Veres I, Juhasz I, et al. Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression. J Clin Invest 2005;115:3166-76.
16. Capaccione KM, Pine SR. The Notch signaling pathway as a mediator of tumor survival. Carcinogenesis 2013;34:1420-30.
17. Hicks C, Pannuti A, Miele L. AssociatingGWASinformationwith the Notch signaling pathway using transcription profiling. Cancer Inform 2011;10: 93-108.
18. Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet Epidemiol 2010;34:816-34.
19. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: An approach for molecular epidemiology studies. J Natl Cancer Inst 2004;96:434-42.
20. Aulchenko YS, Ripke S, Isaacs A, van Duijn CM. GenABEL: An R library for genome-wide association analysis. Bioinformatics 2007;23:1294-6.
21. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-206.
22. Boyle AP, Hong EL, Hariharan M, Cheng Y, Schaub MA, Kasowski M, et al. Annotation of functional variation in personal genomes using RegulomeDB. Genome Res 2012;22:1790-7.
23. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 1988;44:837-45.
24. Sahlgren C, Gustafsson MV, Jin S, Poellinger L, Lendahl U. Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc Natl Acad Sci U S A 2008;105:6392-7.
25. Mullendore ME, Koorstra JB, Li YM, Offerhaus GJ, Fan X, Henderson CM, et al. Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer. Clin Cancer Res 2009;15:2291-301.
26. Panelos J, Batistatou A, Paglierani M, Zioga A, Maio V, Santi R, et al. Expression of Notch-1 and alteration of the E-cadherin/beta-catenin cell adhesion complex are observed in primary cutaneous neuroendocrine carcinoma (Merkel cell carcinoma). Mod Pathol 2009;22:959-68.
27. Pinnix CC, Herlyn M. The many faces of Notch signaling in skin-derived cells. Pigment Cell Res 2007;20:458-65.
28. Holm K, Melum E, Franke A, Karlsen TH. SNPexp - A web tool for calculating and visualizing correlation between HapMap genotypes and gene expression levels. BMC Bioinformatics 2010;11:600.
29. Green AR, Burney C, Granger CJ, Paish EC, El-Sheikh S, Rakha EA, et al. The prognostic significance of steroid receptor co-regulators in breast cancer: co-repressor NCOR2/SMRT is an independent indicator of poor outcome. Breast Cancer Res Treat 2008;110:427-37.
30. Keeton EK, Brown M. Cell cycle progression stimulated by tamoxifenbound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT. Mol Endocrinol 2005;19: 1543-54.
31. Wang LH, Yang XY, Zhang X, Farrar WL. Nuclear receptors as negative modulators of STAT3 in multiple myeloma. Cell Cycle (Georgetown, Tex) 2005;4:242-5.
32. Bhaskara S, Knutson SK, Jiang G, Chandrasekharan MB, Wilson AJ, Zheng S, et al. Hdac3 is essential for the maintenance of chromatin structure and genome stability. Cancer Cell 2010;18:436-47.
33. Wu L, Sun T, Kobayashi K, Gao P, Griffin JD. Identification of a family of mastermind-like transcriptional coactivators for mammalian notch receptors. Mol Cell Biol 2002;22:7688-700.
34. Noda H, Okumura Y, Nakayama T, Miyabe S, Fujiyoshi Y, Hattori H, et al. Clinicopathological significance of MAML2 gene split in mucoepidermoid carcinoma. Cancer Sci 2013;104:85-92.
35. Behboudi A, Enlund F, Winnes M, Andren Y, Nordkvist A, Leivo I, et al. Molecular classification of mucoepidermoid carcinomas-prognostic significance of the MECT1-MAML2 fusion oncogene. Genes Chromosomes Cancer 2006;45:470-81.
36. Canettieri G, Coni S, Della Guardia M, Nocerino V, Antonucci L, Di Magno L, et al. The coactivator CRTC1 promotes cell proliferation and transformation via AP-1. Proc Natl Acad Sci U S A 2009;106: 1445-50.
37. Amelio AL, Fallahi M, Schaub FX, Zhang M, Lawani MB, Alperstein AS, et al. CRTC1/MAML2 gain-of-function interactions with MYC create a gene signature predictive of cancers with CREB-MYC involvement. Proc Natl Acad Sci U S A 2014;111:E3260-8.
38. Filipovic A, Gronau JH, Green AR, Wang J, Vallath S, Shao D, et al. Biological and clinical implications of nicastrin expression in invasive breast cancer. Breast Cancer Res Treat 2011;125:43-53.
39. Paryan M, Mohammadi-Yeganeh S, Samiee SM, Soleimani M, Arefian E, Azadmanesh K, et al. Investigation of deregulated genes of Notch signaling pathway in human T cell acute lymphoblastic leukemia cell lines and clinical samples. Mol Biol Rep 2013;40: 5531-40.
40. Hayashi I, Takatori S, Urano Y, Miyake Y, Takagi J, Sakata-Yanagimoto M, et al. Neutralization of the gamma-secretase activity by monoclonal antibody against extracellular domain of nicastrin. Oncogene 2012;31: 787-98.